Exclusion criteria for deferred workup in eligible patients (N = 1653)
| . | n (%) with criterion . | n (%) with only criterion . |
|---|---|---|
| Anticoagulation* | 447 (27.0) | 329 (19.9) |
| Empiric anticoagulation treatment in primary care before referral | 328 (19.8) | 245 (14.8) |
| Regular prescription of anticoagulation treatment | 129 (7.8) | 76 (4.6) |
| Both empiric and regular use of anticoagulation treatment | 10 (0.6) | 8 (0.5) |
| Patient objects to discharge | 192 (11.6) | 117 (7.1) |
| Physician deems discharge unsafe | 189 (11.4) | 89 (5.4) |
| Suspected active or recent bleeding | 70 (4.2) | 11 (0.7) |
| GFR <45 mL/min per 1.73 m2 | 66 (4.0) | 17 (1.0) |
| Active cancer or chemotherapy within the past 6 mo | 65 (3.9) | 23 (1.4) |
| Major risk factors for bleeding | 59 (3.6) | 4 (0.2) |
| Logistical challenges for at-home observation | 45 (2.7) | 16 (1.0) |
| Workup expected to complete within 2 h | 44 (2.7) | 28 (1.7) |
| Medications possibly interacting with rivaroxaban | 44 (2.7) | 10 (0.6) |
| Hemoglobin <11 g/dL and/or thrombocytes <100 × 109/L | 39 (2.4) | 6 (0.4) |
| Pregnancy or lactation | 23 (1.4) | 14 (0.8) |
| Suspected concurrent PE | 22 (1.3) | 2 (0.1) |
| Comorbidities necessitating admission | 20 (1.2) | 2 (0.1) |
| Suspected ischemia or eligibility for thrombolysis | 4 (0.2) | 0 (0) |
| Liver disease† | 2 (0.1) | 0 (0) |
| . | n (%) with criterion . | n (%) with only criterion . |
|---|---|---|
| Anticoagulation* | 447 (27.0) | 329 (19.9) |
| Empiric anticoagulation treatment in primary care before referral | 328 (19.8) | 245 (14.8) |
| Regular prescription of anticoagulation treatment | 129 (7.8) | 76 (4.6) |
| Both empiric and regular use of anticoagulation treatment | 10 (0.6) | 8 (0.5) |
| Patient objects to discharge | 192 (11.6) | 117 (7.1) |
| Physician deems discharge unsafe | 189 (11.4) | 89 (5.4) |
| Suspected active or recent bleeding | 70 (4.2) | 11 (0.7) |
| GFR <45 mL/min per 1.73 m2 | 66 (4.0) | 17 (1.0) |
| Active cancer or chemotherapy within the past 6 mo | 65 (3.9) | 23 (1.4) |
| Major risk factors for bleeding | 59 (3.6) | 4 (0.2) |
| Logistical challenges for at-home observation | 45 (2.7) | 16 (1.0) |
| Workup expected to complete within 2 h | 44 (2.7) | 28 (1.7) |
| Medications possibly interacting with rivaroxaban | 44 (2.7) | 10 (0.6) |
| Hemoglobin <11 g/dL and/or thrombocytes <100 × 109/L | 39 (2.4) | 6 (0.4) |
| Pregnancy or lactation | 23 (1.4) | 14 (0.8) |
| Suspected concurrent PE | 22 (1.3) | 2 (0.1) |
| Comorbidities necessitating admission | 20 (1.2) | 2 (0.1) |
| Suspected ischemia or eligibility for thrombolysis | 4 (0.2) | 0 (0) |
| Liver disease† | 2 (0.1) | 0 (0) |